 |
|
Benefits of Early Systemic Corticosteroid in Clinical Deterioration of Post–COVID-19 Interstitial Lung Disease
Tai Joon An, Ye Jin Lee, Ji Eun Park, Eung Gu Lee, Youlim Kim, Sung-Yoon Kang, Hyonsoo Joo, Joon Young Choi
Tuberc Respir Dis. 2022;85(4):358-360. Published online 2022 Aug 11 DOI: https://doi.org/10.4046/trd.2022.0072
|
|
Citations to this article as recorded by
 Effects of pharmacotherapy on post-COVID-19 pulmonary fibrosis: Systemic review
Olga Butranova, Elena Baybulatova, Sergey Zyryanov, Yury Kustov, Y. Alibek
BIO Web of Conferences.2024; 100: 01010. CrossRef Corticosteroid Therapy Duration and Dosage According to the Timing of Treatment Initiation for Post-COVID-19 Organizing Pneumonia
Chang-Seok Yoon, Hwa-Kyung Park, Jae-Kyeong Lee, Bo-Gun Kho, Tae-Ok Kim, Hong-Joon Shin, Yong-Soo Kwon, Sung-Chul Lim, Yu-Il Kim
Chonnam Medical Journal.2024; 60(3): 166. CrossRef Perspectives on Post-COVID-19 Pulmonary Fibrosis Treatment
Elena Cojocaru, Tudor Cojocaru, Giulia Mihaela Pînzariu, Ioana Vasiliu, Ioana Armașu, Cristian Cojocaru
Journal of Personalized Medicine.2023; 14(1): 51. CrossRef
|